Ikorel (Nicorandil) is applied in therapeutic domains involving the symptomatic management of stable angina pectoris. It is applied across domains where additional symptomatic support is needed, primarily to help with symptoms related to physical discomfort in adults with chronic heart conditions.

The medicine is used for managing symptoms of stable angina; it may help address symptom clusters that may become intense or disruptive, and is considered relevant when symptoms interfere with daily comfort. This treatment is often applied in scenarios where additional management of discomfort is required, such as in conditions where symptoms may intensify temporarily. The use of this medication may assist with supporting functional stability and supports patients during episodes of heightened discomfort.

It may be part of symptomatic management that helps address limitations related to exercise tolerance and is considered relevant in contexts involving heightened systemic burden. It is applied across domains where additional symptomatic support is needed, which contributes to patients coping more steadily with symptom fluctuations, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Supportive Management for Angina Chest Pain The medicine is commonly used to help with symptoms related to physical discomfort arising from coronary artery disease, often when additional symptomatic support is needed.

Official Eligibility and Contraindications for Ikorel (Nicorandil)

Use of Ikorel is primarily limited to adults and is defined by several absolute exclusions (contraindications) and required precautions, based strictly on regulatory labeling.

Classification	Who Must Not Use Ikorel (Contraindications)
Cardiovascular Status	Patients with cardiogenic shock, severe hypotension, acute pulmonary oedema, hypovolaemia (depleted blood volume), or left ventricular failure with low filling pressures are strictly excluded.
Co-medications	Concomitant use with Phosphodiesterase 5 Inhibitors (e.g., sildenafil) or soluble Guanylate Cyclase Stimulators (e.g., riociguat) is contraindicated due to the risk of a serious, life-threatening drop in blood pressure.
Allergy	Patients with a known hypersensitivity to nicorandil, nicotinic acid, or any excipients.

Population and Special Considerations

• Age: Use in the paediatric population (children and adolescents) is not recommended because safety and efficacy have not been established in this age group. No special dose reduction is required for older adults.
• Pregnancy and Lactation: Ikorel should not be used during pregnancy unless considered essential by the physician, as there is limited human experience. Use is not recommended during breastfeeding, as it is unknown whether the substance is excreted in human milk.
• Organ Function and Comorbidity: No special dose adjustment is required for patients with renal or hepatic impairment. However, caution is advised for patients with Heart Failure class NYHA III or IV due to a lack of clinical data.

Interactions with other medicines and products

The official regulatory profile for Ikorel (Nicorandil) emphasizes specific combinations that are either prohibited or require careful regulatory caution due to potential drug interactions.

---

Contraindicated Combinations

Co-administration with Phosphodiesterase 5 (PDE5) inhibitors (such as Sildenafil, Tadalafil, or Vardenafil) and Soluble Guanylate Cyclase (sGC) stimulators (such as Riociguat) is absolutely prohibited (contraindicated). This restriction is mandated due to the severe and life-threatening risk of synergistic hypotension (extremely low blood pressure).

---

Pharmacodynamic Potentiation

Nicorandil may potentiate the blood pressure-lowering effects of antihypertensive agents, other vasodilators, or tricyclic antidepressants. Consumption of alcohol may also increase the hypotensive effect. Caution is advised when Nicorandil is combined with NSAIDs, Aspirin, or Corticosteroids due to an officially documented increased risk of severe gastrointestinal complications, including ulceration and haemorrhage.

---

Other Documented Interactions

Caution is necessary when co-administering Nicorandil with products that may increase potassium levels (such as potassium supplements or certain salt substitutes) due to the risk of hyperkalaemia. This risk is considered elevated for patients with reduced kidney function. Studies have determined that co-administration with the metabolic enzyme modulators Cimetidine and Rifampicin does not result in a clinically relevant change to Ikorel's concentration or overall exposure.

Dual Activation of K ATP Channels and Nitric Oxide Signaling

Nicorandil's pharmacological action is derived from its unique ability to simultaneously act as an ATP-sensitive potassium ( K ATP) channel opener and a nitric oxide ( NO) donor. The dual nature of the molecule engages two separate pathways that converge to relax the walls of blood vessels. This concurrent modulation of both membrane potential and intracellular secondary messengers (cGMP) influences vascular smooth muscle tone.

---

Modulation of Vascular Tone and Hemodynamic Parameters

The activation of K ATP channels causes the outflow of potassium ions, leading to cell hyperpolarization and subsequent widening of the arterial resistance vessels. The released NO, through the cGMP pathway, causes relaxation primarily of the venous capacitance vessels. This balanced vasodilation results in a physiological adjustment, which decreases the volume of blood returning to the heart (preload) and lowers the systemic pressure against which the heart must pump (afterload).

---

Targeted Myocardial Cytoprotection

Beyond its hemodynamic effects, Nicorandil engages in a protective mechanism by activating mitochondrial K ATP channels within the heart muscle cells. This action initiates signaling that helps preserve the cells' energy-producing capacity and membrane stability. The resulting cytoprotective effect is a physiological consequence of the drug's mechanism.

Ikorel is administered via the oral route as a tablet for the long-term symptomatic management of chronic stable angina. The general principle of use is a twice-daily (bid) regimen, typically involving one dose in the morning and one in the evening, independent of food intake.

---

Standard Dosing and Titration

The medicine is used according to a carefully defined titration schedule. The standard starting dose for adults is 10 mg taken twice a day. For patients who may be susceptible to headache, a lower starting dose of 5 mg twice daily may be used initially. The dosage is subsequently adjusted based on the patient's individual needs and tolerance, with the usual therapeutic maintenance dose ranging from 10 mg to 20 mg twice daily. This procedural adjustment logic establishes the medication as part of a long-term treatment plan. The maximum recommended dose that may be administered is 40 mg twice daily.

---

Administration Requirements

Administration is independent of food intake. To ensure the correct action, the tablet must always be swallowed whole with water and must not be crushed or chewed. Due to the tablet's moisture sensitivity, it must remain in its original blister packaging until the moment of ingestion. The scoreline on the 20 mg tablet exists solely to facilitate swallowing and should not be used to divide the dose into equal halves.

---

Population Rules

Specific high-level rules apply to certain populations: no routine dose adjustment is required for older adults; however, the lowest effective dose should be used. The medication is not recommended for use in pediatric patients as efficacy and safety data are not established.

Research evidence / Overview of Studies for Ruxolitinib

Evidence for use in Myelofibrosis (MF)

Randomized controlled trials (RCTs) were conducted exploring Ruxolitinib in myelofibrosis. These studies compared the drug to either an inactive placebo or best available therapy in patients diagnosed with intermediate-2 or high-risk MF. Research was studied for its potential influence on patient-reported outcomes describing perceived discomfort and outcomes related to systemic or functional imbalance.

Studies monitored changes in spleen volume and patient-reported outcomes describing perceived discomfort during the study period. However, the findings are accompanied by research limitations. A high rate of crossover from the control group to the study drug was associated with uncertainty regarding long-term comparison of overall survival rates. Data for certain groups, particularly those with very low platelet counts, remain insufficient, and the results apply only to the populations studied.

---

Evidence for use in Polycythemia Vera (PV)

An RCT was evaluated in patients with PV who had an inadequate response to, or could not tolerate, treatment with hydroxyurea. This research examined outcomes related to systemic or functional imbalance, such as control of high red blood cell counts (hematocrit), changes in spleen size, and patient-reported outcomes describing perceived discomfort.

Research so far indicates that specific measurements of hematocrit control and spleen size reduction were reported in a defined number of patients receiving the drug. Long-term effects are not fully established for all outcomes, and the existing studies provide limited information regarding the drug's use as a first-line therapy for newly diagnosed patients. Furthermore, subgroup findings are uncertain for specific types of intolerance to prior hydroxyurea treatment.

---

Evidence for use in Acute and Chronic Graft-Versus-Host Disease (GVHD)

RCTs were studied for both acute and chronic GVHD in patients whose condition did not improve after standard steroid treatment (steroid-refractory). Research monitored the overall response rate (ORR) and complete response rate (CRR) at defined time points. Studies reported how symptom scores evolved and described patterns related to the proportion of patients who achieved a reduction in their required steroid dosage in the chronic GVHD cohort. Follow-up durations were limited in certain key trials, and long-term effects are not fully established.

Key Studies & References FDA Drug Approval Information: Jakafi (Ruxolitinib) Indications and Usage

Common questions about Ikorel (FAQ)

---

Q: What is Ikorel (nicorandil) primarily used for?

A: Ikorel, which contains the active ingredient nicorandil, is typically used to manage and prevent episodes of stable angina pectoris (chest pain caused by reduced blood flow to the heart). Its use is generally intended for individuals who have not responded adequately to or cannot tolerate other standard anti-anginal treatments.

---

Q: How does Ikorel work?

A: Nicorandil, the active ingredient in Ikorel, is described in regulatory information as having a dual mechanism. It acts as a potassium channel activator and also possesses nitrate-like properties. These actions may help to relax and widen both the large coronary arteries and the systemic resistance vessels. This is understood to potentially improve blood flow to the heart muscle and reduce the workload on the heart.

---

Q: Can Ikorel be stopped suddenly?

A: Official prescribing information advises that treatment with Ikorel should not be stopped abruptly. Suddenly discontinuing the medication may potentially lead to a worsening of the symptoms of angina. Any decision to adjust or stop treatment should be made gradually and only under the direction of a healthcare professional.

---

Q: What are the common side effects of Ikorel?

A: Like all medicines, Ikorel may be associated with side effects, though not everyone experiences them. Regulatory documents indicate that some common reported side effects include headache, flushing (a reddening of the face), and dizziness. It is important to discuss any side effects with your prescriber, especially if they are persistent or concerning.

---

Q: Can Ikorel interact with other medications?

A: Yes, there is a potential for interactions with certain medications. It is crucial to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and supplements you are currently taking. Particular caution is generally advised when combining Ikorel with other medicines that are known to lower blood pressure, or with certain medicines used for erectile dysfunction (e.g., phosphodiesterase type 5 inhibitors) as this combination is typically contraindicated due to the risk of severe blood pressure drops.

---

The storage and disposal of Ikorel (nicorandil) tablets must strictly follow regulatory requirements to maintain the drug’s stability and potency.

Storage Requirements

Ikorel must be stored at a temperature below 25 C in a cool, dry place. Due to the tablets' sensitivity to moisture, they must be kept in their original package to protect them, which includes a desiccant in the blister strip [1.2, 3.4]. The desiccant must not be swallowed [1.5].

To ensure the drug remains stable for its labeled shelf-life, each individual blister strip should be used within 30 days of opening [1.1, 3.2]. The medicine must also be kept out of the sight and reach of children [1.5].

Disposal Instructions

All unused, expired, or waste material must be disposed of in accordance with local requirements [3.3]. In many regions, this involves returning the medicine to a pharmacy for safe disposal [1.2].